CM
Therapeutic Areas
Terns Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TERN-701 | Chronic Myeloid Leukemia (CML) | Phase 3 |
| Metabolic / Obesity Programs | Undisclosed Metabolic Disease / Obesity | Preclinical / Early Clinical |
| Oncology Programs | Undisclosed Oncology Indications | Preclinical / Early Clinical |
Leadership Team at Terns Pharmaceuticals
AB
Amy Burroughs
Chief Executive Officer
AG
Andrew Gengos
Chief Financial Officer and Head of Corporate Development
SH
Scott Harris
Chief Development and Operations Officer
MS
Melita Sun Jung
Chief Business Officer
EK
Emil Kuriakose
Chief Medical Officer
RA
Robin Andrulevich
Chief People Officer
JJ
Jeff Jasper
SVP, Senior Distinguished Research Fellow
JK
James Kanter
SVP, CMC
YQ
Yasameen Qazen
SVP, Regulatory Affairs and Quality Assurance
DS
Debra Sieminski
SVP, Medical Affairs